BiotechTube

Abatacept (Orencia)

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ANCA-associated Vasculitis

Conditions

ANCA-associated Vasculitis

Trial Timeline

Nov 1, 2007 → Nov 1, 2008

NCT ID
NCT00482066

About Abatacept (Orencia)

Abatacept (Orencia) is a phase 2 stage product being developed by Bristol Myers Squibb for ANCA-associated Vasculitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00482066. Target conditions include ANCA-associated Vasculitis.

What happened to similar drugs?

0 of 2 similar drugs in ANCA-associated Vasculitis were approved

Approved (0) Terminated (0) Active (2)
🔄rituximab + PlaceboRochePhase 3
🔄Avacopan + Prednisone + Cyclophosphamide + Rituximab + AzathioprineAmgenPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00482066Phase 2Terminated

Competing Products

3 competing products in ANCA-associated Vasculitis

See all competitors
ProductCompanyStageHype Score
rituximab + PlaceboRochePhase 3
40
CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids + CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoidsAmgenPhase 2
35
Avacopan + Prednisone + Cyclophosphamide + Rituximab + AzathioprineAmgenPhase 3
40